Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced positive topline safety and efficacy data from the first, lowest dose cohort of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Ultragenyx Announces Positive Topline Results from First Cohort of Phase 1/2 Clinical Study of DTX401 Gene Therapy in Glycogen Storage Disease Type IaJanuary 4, 2019 8:30 AM Celgene, TESARO Deals Positive for SMID Cap Biotech - SunTrustJanuary 3, 2019 10:34 AM Raymond James Downgrades Ultragenyx Pharma (RARE) to Market PerformJanuary 2, 2019 4:25 AM